The Food and Drug Administration’s (FDA) Commissioner’s National Priority Voucher (CNPV) program is one of the agency’s most aggressive drug regulation experiments in years. Rolled out in June 2025 under Commissioner Marty Makary, the CNPV program offers the opportunity to compress a full drug or biologic review into roughly 30–60 days, instead of the usual 10–12 months, for a small set of products hand-picked as serving U.S. “national priorities.” While this push for ultra-fast review creates opportunities for agency efficiency, there are potentially serious drawbacks with the current design of the program. 

The CNPV’s focus on “national priorities” is framed as a response to two connected threats, the worsening health of the U.S. population and the fragility of drug supply chains. Against that backdrop, the agency set out five pillars for a CNPV: addressing a U.S. public health crisis, delivering “innovative cures,” tackling large unmet medical needs, onshoring manufacturing, and increasing affordability. The first two waves of awards show how broadly those priorities are being interpreted. FDA’s initial 15 voucher recipients span fertility, obesity, Type 1 diabetes, vaping addiction, infectious disease, multiple cancers, sickle cell disease, rare blindness and deafness, porphyria, and two domestically manufactured generics. (See the American Action Forum’s comprehensive insight on the CNPV program.) 

What makes the CNPV program truly different is not just the product mix but the logic behind it. Traditional expedited review pathways – Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review – are grounded in statute and built around clinical criteria: serious disease, unmet need, and meaningful improvements in outcomes. These programs are widely available to any sponsor that can meet those standards, and the benefits are relatively well-defined, such as cutting the review clock from 10 months to 6 months under Priority Review. Other Priority Review Voucher programs for tropical and rare pediatric diseases are similarly codified and transferable: Companies can earn a voucher and sell it to someone else for a faster review. 

The CNPV program, by contrast, is far more discretionary. While it layers on top of existing expedited review pathways, it is explicitly intended to address “national priorities,” not just disease severity. A product can qualify because it is manufactured in the United States, because the sponsor offers formal pricing concessions, or because it aligns with a federal narrative about readiness or affordability. The voucher cannot be sold, must be used quickly, and aims for a decision in 30–60 days, a sharp divergence from normal FDA timelines. That makes the CNPV program less a scientifically based standard and more a commissioner-driven overlay for a set of products that fit a broader (potentially unrelated) policy agenda. 

That design has obvious upsides and equally obvious risks. On the upside, the CNPV program gives FDA a way to concentrate resources on drugs that could deliver unusually large public health or strategic returns and serves as a test bed for more collaborative, “all-hands” reviews that bring key experts into the process earlier. 

The trade-offs, however, are hard to ignore. Because the CNPV program was not created by Congress, critics argue that it effectively establishes a new class of ultra-fast review timelines and incentives without clear statutory guardrails or public rulemaking. Lawmakers and policy experts have already questioned whether a program that can deliver 30-day decisions to politically salient products, based on broad and somewhat opaque criteria, amounts to a handout to favored companies. There are also worries about how these multidisciplinary reviews interact with user-fee performance goals and FDA’s obligation to keep the rest of its docket moving on time. 

Operationally, concentrating expert reviewers on a handful of CNPV applications could slow down non-voucher reviews or burn out staff. Compressing a full scientific review into 1–2 months leaves less room to explore odd data signals or seek further input. And because selection rests on “national interest” factors, the program blurs the line between scientific regulation and industrial or trade policy, inviting accusations of politicization if controversial products benefit. Finally, the CNPV program risks deepening a two-tier system in which sponsors working on conditions that are a focus of public attention are most likely to qualify, while smaller developers or those in less headline-grabbing areas struggle for attention.  

Without clearer criteria, transparent reporting on trade-offs, and some engagement from Congress on legal footing, the program could come to be seen less as a targeted tool for national priorities and more as a high-stakes exception to the normal rules. Whether this audacious bet pays off will depend less on how many high-profile drugs it accelerates and more on whether FDA can show that the speed it bought for a few did not come at the expense of everyone else.